Stock Research: Lotus Pharmaceutical

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Lotus Pharmaceutical

TSEC:1795 TW0001795003
17
  • Value
    26
  • Growth
    8
  • Safety
    Safety
    40
  • Combined
    1
  • Sentiment
    83
  • 360° View
    360° View
    17
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Lotus Pharmaceutical Co Ltd is a Taiwan-based company focused on manufacturing and selling generic drugs, including solid preparations like tablets and capsules. The company operates in oral anti-cancer drugs, cardiovascular disease drugs, central nervous system drugs, women's health products, osteoporosis drugs, and mental disease drugs, and is also involved in drug research, development, clinical testing, and product licensing. Its main markets are Taiwan, South Korea, the United States, China mainland, Japan, Europe, and Southeast Asia. In the last fiscal year, the company had a market cap of $1963 million, profits of $333 million, and revenue of $567 million.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 17 (better than 17% compared with alternatives), overall professional sentiment and financial characteristics for the stock Lotus Pharmaceutical are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Lotus Pharmaceutical. The consolidated Sentiment Rank has a good rank of 83, which means that professional investors are more optimistic about the stock than for 83% of alternative investment opportunities. But all other ranks are below average. The consolidated Value Rank has a rank of 40, which means that the share price of Lotus Pharmaceutical is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. The consolidated Growth Rank also has a low rank of 8, meaning that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. This means that growth is lower than for 8% of competitors in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 26 which means that the company has a riskier financing structure than 74% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Index
FTSE Taiwan
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Growth
Shows a company's growth potential.
High Growth Tough Times
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
40 38 38 65
Growth
8 80 87 85
Safety
Safety
26 13 18 18
Sentiment
83 100 90 69
360° View
360° View
17 69 70 79
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
70 93 91 95
Opinions Change
13 50 50 50
Pro Holdings
n/a 100 96 4
Market Pulse
100 100 46 79
Sentiment
83 100 90 69
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
40 38 38 65
Growth
8 80 87 85
Safety Safety
26 13 18 18
Combined
1 38 42 57
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
86 74 65 91
Price vs. Earnings (P/E)
30 24 24 69
Price vs. Book (P/B)
28 22 18 47
Dividend Yield
59 67 64 62
Value
40 38 38 65
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
22 84 82 67
Profit Growth
41 44 69 76
Capital Growth
34 55 51 25
Stock Returns
18 64 71 89
Growth
8 80 87 85
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
19 11 11 8
Refinancing
36 26 29 43
Liquidity
39 22 39 24
Safety Safety
26 13 18 18

Similar Stocks

Discover high‑ranked alternatives to Lotus Pharmaceutical and broaden your portfolio horizons.

Japan Airlines

TSE:9201
Country: Japan
Industry: Airlines
Size: X-Large
Full Stock Analysis

Tsumura

TSE:4540
Country: Japan
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Sumitomo Forestry

TSE:1911
Country: Japan
Industry: Homebuilding
Size: X-Large
Full Stock Analysis

Hisamitsu Pharmaceutical

TSE:4530
Country: Japan
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.